MUC1 and cancer: Recent evidence suggests that the induction of a strong anti-MUC1 response in cancer patients may require the activation of specific T helper cells via MHC class II presented peptide and glycopeptide epitopes, a process that is controlled by site-specific O-glycosylation (Vlad et al, 2002).